Meanwhile, another $70 million to $80 million of IPO proceeds is expected to fund the launch a phase 1b study of its second ...

No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week. Read ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

US biotech Aktis Oncology has filed IPO documents with the Securities and Exchange Commission (SEC), in what could be the ...

Startup Parabilis Medicines has raised $305 million in new funding, money that will help bring its lead drug for a variety of ...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare ...

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are ...

China-based BioRay Biopharmaceutical has submitted an application to list on the Hong Kong Stock Exchange, setting out plans ...

Backed by Eli Lilly, Aktis Oncology's $318M IPO marks 2026's first major biotech public offering, signaling renewed investor ...